{
    "nct_id": "NCT04188951",
    "official_title": "HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer High Risk Pathologic Features Following Surgical Salvage and Are Not Eligible for Post-operative Radiation Therapy",
    "inclusion_criteria": "* Patients must be 18 years or older, of either gender, with the ability to consent to participation in the study.\n* Patients must have a history of squamous cell carcinoma of the head and neck involving any sub-site in the head and neck area except nasopharynx, paranasal sinuses, and salivary gland tumors.\n* All patients must have recurred following definitive therapy with any combination of surgery, radiation, and/or chemotherapy.\n* All patients must have undergone salvage surgery in an attempt to excise all recurrent disease.\n* Salvage radiation therapy must not be an option available to the patient.\n* Patients must have high risk features such extra nodal invasion, positive margins, perineural invasion or vascular embolism.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "* Patients with macroscopic residual disease\n* Patient is eligible for radiation therapy.\n* Performance status more than 2.\n* Contraindications for immunotherapy, autoimmune disease, allergy to medication, steroid use at baseline.\n* Patients with other previous cancers excluding CIN, DCIS, non-melanoma skin cancers\n* Patients previously treated with immunotherapy <12months prior\n* Patients with synchronous cancers \"not included in the inclusion criteria\"",
    "miscellaneous_criteria": ""
}